Implementing PAT, One Step at a Time

By Robert Cogdill, Ph.D., Industrial Research Coordinator, Center for Pharmaceutical Technology, Duquesne University
PharmaManufacturing.com
If FDA’s guidance and its risk-based inspection focus weren’t reason enough for pharma companies to implement Process Analytical Technology (PAT), its benefits in the areas of quality improvement, validation, manufacturing yield and efficiency, and reductions in inventory and overhead ought to spur increased adoption, urges Robert Cogdill, Ph.D., of Duquesne University's Center for Pharmaceutical Technology. Those who missed his presentation at Interphex last week can access it here.